Sangamo Biosciences, Inc. (NASDAQ:SGMO)

CAPS Rating: 2 out of 5

The Company deals in the research, development and commercialization of DNA-binding proteins for the therapeutic regulation and modification of disease-related genes.

Recs

0
Player Avatar pchop123 (79.44) Submitted: 11/12/2012 8:23:11 AM : Outperform Start Price: $5.14 SGMO Score: +5.18

Promising if clinical results go OK

Featured Broker Partners


Advertisement